Enovis Co. (NYSE:ENOV) Shares Purchased by UMB Bank n.a.

UMB Bank n.a. raised its stake in Enovis Co. (NYSE:ENOV) by 128.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 778 shares of the company’s stock after buying an additional 437 shares during the period. UMB Bank n.a.’s holdings in Enovis were worth $34,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pinnacle Bancorp Inc. boosted its position in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after buying an additional 300 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Enovis in the third quarter worth $55,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after acquiring an additional 371 shares during the last quarter. FMR LLC increased its position in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after purchasing an additional 484 shares in the last quarter. Finally, Heritage Family Offices LLP acquired a new position in Enovis in the 3rd quarter valued at about $206,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ENOV. JMP Securities began coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. Finally, Evercore ISI lowered their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $65.86.

Enovis Stock Up 1.1 %

Shares of NYSE:ENOV opened at $47.78 on Friday. The company has a 50 day moving average of $45.93 and a two-hundred day moving average of $44.46. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of -21.82 and a beta of 1.94.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.56 EPS. As a group, analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.